GlassScriptPhysician profile
Emily Sauce
NPI 1639819451
$4,930.53
in general payments reported to CMS, 2019-2025
20 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $661 · 2024: $2,386 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,832 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,831.53 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,031.68 | 2023-2025 | |
| Abbvie INC. | $768.93 | 2023-2025 | |
| Lilly USA, LLC | $621.82 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Scientific Affairs, LLC | $347.88 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $321.05 | 2024-2025 | |
| Incyte Corporation | $264.11 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $233.52 | 2024 | Sotyktu |
| Ucb, INC. | $195.09 | 2024-2025 | Bimzelx |
| Kyowa Kirin, INC. | $181.91 | 2023-2024 | Poteligeo |
| Organon LLC | $163.12 | 2025 | Vtama |
| Pfizer INC. | $158.86 | 2024-2025 | |
| Janssen Biotech, INC. | $136.22 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.99 | 2024 | Spevigo |
| Dermavant Sciences, INC. | $112.67 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $108.29 | 2025 | Nemluvio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $91.56 | 2023 | Uvadex |
| Sobi, INC | $22.30 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.39 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $13.79 | 2024 | Welireg, Keytruda |
| Almirall LLC | $13.35 | 2024 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Sauce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.